Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310705 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL16311794 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL15591909 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL16962406 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL16962405 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL1660877 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL3408785 | 0.77 | PTGDR2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL15269917 | 0.74 | HTR2C (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3PNMT | |
| SCHEMBL19682735 | 0.74 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL31071936 | 0.74 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2457925-A1 | Process for preparing a macrocyclic modulator of the ghrelin receptor and intermediates | Tranzyme Pharma, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | CHRNB2 2420/4885CHRNA4 2124/4885CHRNB4 2354/4885 |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | GPR119, GPR52, GPR55 | CHRNB2 2420/4885CHRNA4 2124/4885CHRNB4 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.